Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders (Q24187995)

6

0 references

author name string

Rasmita Ori

1

0 references

Taryn Amos

2

0 references

Hanna Bergman

3

0 references

Jonathan C Ipser

Cochrane Database of Systematic Reviews

5

0 references

language of work or name

English

0 references

publication date

10 May 2015

0 references

published in

0 references

issue

5

0 references

page(s)

CD007803

0 references

cites work

Prescriptive variables for d-cycloserine augmentation of exposure therapy for posttraumatic stress disorder.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Sleep quality predicts treatment outcome in CBT for social anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

The impact of benzodiazepine management in the randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

The research network PANIC-NET: improving the treatment of panic disorder - from a better understanding of fear circuit mechanisms to more effective psychological treatment and routine care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

d-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Does d-Cycloserine Augmentation of CBT Improve Therapeutic Homework Compliance for Pediatric Obsessive-Compulsive Disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Augmentation of exposure therapy with post-session administration of D-cycloserine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine for the augmentation of an attentional training intervention for trait anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

The effect of D-cycloserine on subliminal cue exposure in spider fearful individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Sex differences in fear conditioning in posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

21 January 2018

2 references

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

21 January 2018

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

7 January 2021

Evidence-based pharmacological treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Treatment-resistant panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Effects of D-cycloserine on extinction: translation from preclinical to clinical work

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

The child PTSD Symptom Scale: a preliminary examination of its psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Interpretation and choice of effect measures in epidemiologic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

A re-evaluation of random-effects meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Is it Beneficial to Add Pharmacotherapy to Cognitive-Behavioral Therapy when Treating Anxiety Disorders? A Meta-Analytic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Cognitive enhancers for anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Clinical practice. Obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Effects of D-cycloserine on extinction of conditioned freezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Reconsolidation and extinction of conditioned fear: inhibition and potentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Quality of life in individuals with anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Measuring the global burden of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Treatment non-response in OCD: methodological issues and operational definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Applying learning principles to the treatment of post-trauma reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Use of benzodiazepines in anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

The role of NMDA glutamate receptors, PKA, MAPK, and CAMKII in the hippocampus in extinction of conditioned fear.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Why sources of heterogeneity in meta-analysis should be investigated

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Glutamatergic drugs for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Facilitation of conditioned fear extinction by d-cycloserine is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase cascades and requires de novo protein synthesis in basolateral nucleus of amygdala

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

Special Topics in Statistics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

A high-throughput clinical assay for testing drug facilitation of exposure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

7 January 2021

A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

7 January 2021

Efficacy of combined pharmacotherapy and psychotherapy versus monotherapy in the treatment of anxiety disorders.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

7 January 2021

Treatment of social phobia through pure self-help and therapist-augmented self-help

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

7 January 2021

Amygdalar NMDA receptors are critical for new fear learning in previously fear-conditioned rats.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

7 January 2021

The role of ventromedial prefrontal cortex in the recovery of extinguished fear

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

7 January 2021

Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007803.PUB2

7 January 2021

10.1002/14651858.CD007803.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_gdm5btrvfjbrdbk4m7634dvaqe

4497402

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gdm5btrvfjbrdbk4m7634dvaqe

24 November 2022

mapped directly with Wikidata item

4497402

1 reference

Consolidated OpenCitations Corpus – April 2017

https://api.fatcat.wiki/v0/release/gdm5btrvfjbrdbk4m7634dvaqe

1 reference

24 November 2022

mapped directly with Wikidata item

PubMed publication ID

25957940

1 reference

Consolidated OpenCitations Corpus – April 2017